Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells

Journal of Immunology

Volumn 182, Issue 9, 2009, Pages 5477-5487

  Kiesel, Jennifer R ^a   Buchwald, Zachary S ^a   Aurora, Rajeev ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OSTEOCLAST DIFFERENTIATION FACTOR; OVALBUMIN; PROTEIN KINASE ZAP 70; RANTES; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BONE DISEASE; BONE REMODELING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; FEEDBACK SYSTEM; IMMUNOREGULATION; INFLAMMATORY DISEASE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CLASSIFICATION; CYTOLOGY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MOUSE MUTANT; SECRETION;

ANIMALS; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINES; CROSS-PRIMING; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOPHENOTYPING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOCLASTS; OVALBUMIN;

EID: 66949172165     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803897     Document Type: Article

References (111)

1. Hattner, R., B. N. Epker, and H. M. Frost. 1965. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206: 489-490.
2. Vaananen, H. K. 1993. Mechanism of bone turnover. Ann. Med. 25: 353-359.
3. Walsh, M. C., N. Kim, Y. Kadono, J. Rho, S. Y. Lee, J. Lorenzo, and Y. Choi. 2006. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24: 33-63.
4. Lee, N. K., H. Sowa, E. Hinoi, M. Ferron, J. D. Ahn, C. Confavreux, R. Dacquin, P. J. Mee, M. D. McKee, D. Y. Jung, et al. 2007. Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456-469.
5. David, J. P. 2007. Osteoimmunology: a view from the bone. Adv. Immunol. 95: 149-165.
6. Sato, K., A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, et al. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203: 2673-2682. (Pubitemid 44833343)
7. Takayanagi, H. 2005. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83: 170-179. (Pubitemid 40487405)
8. Taubman, M. A., P. Valverde, X. Han, and T. Kawai. 2005. Immune response: the key to bone resorption in periodontal disease. J. Periodontol. 76: 2033-2041.
9. Teng, Y. T. 2006. Protective and destructive immunity in the periodontium: Part 2. T-cell-mediated immunity in the periodontium. J. Dent. Res. 85: 209-219. (Pubitemid 43827727)
10. Theill, L. E., W. J. Boyle, and J. M. Penninger. 2002. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20: 795-823.
11. Anderson, D. M., E. Maraskovsky, W. L. Billingsley, W. C. Dougall, M. E. Tometsko, E. R. Roux, M. C. Teepe, R. F. DuBose, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179.
12. Wong, B. R., R. Josien, S. Y. Lee, B. Sauter, H. L. Li, R. M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186: 2075-2080.
13. Takayanagi, H., S. Kim, K. Matsuo, H. Suzuki, T. Suzuki, K. Sato, T. Yokochi, H. Oda, K. Nakamura, N. Ida, et al. 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416: 744-749. (Pubitemid 34429151)
14. Zheng, H., X. Yu, P. Collin-Osdoby, and P. Osdoby. 2006. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts: an autocrine negative feedback mechanism triggered by RANKL-induced interferon-β via NF-κB that restrains osteoclastogenesis and bone resorption. J. Biol. Chem. 281: 15809-15820. (Pubitemid 43848471)
15. Triantaphyllopoulos, K. A., R. O. Williams, H. Tailor, and Y. Chernajovsky. 1999. Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin-12, and tumor necrosis factor α production by interferon-β gene therapy. Arthritis Rheum. 42: 90-99.
16. Fox, S. W., and T. J. Chambers. 2000. Interferon-γ directly inhibits TRANCE-induced osteoclastogenesis. Biochem. Biophys. Res. Commun. 276: 868-872.
17. Takahashi, N., G. R. Mundy, and G. D. Roodman. 1986. Recombinant human interferon-γ inhibits formation of human osteoclast-like cells. J. Immunol. 137: 3544-3549. (Pubitemid 17193314)
18. Geboes, L., B. De Klerck, M. Van Balen, H. Kelchtermans, T. Mitera, L. Boon, C. De Wolf-Peeters, and P. Matthys. 2007. Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-γ receptor by triggering tumor necrosis factor α-driven osteoclastogenesis. Arthritis Rheum. 56: 2595-2607. (Pubitemid 47237278)
19. O' Gradaigh, D., D. Ireland, S. Bord, and J. E. Compston. 2004. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor α, interleukin 1, and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis. 63: 354-359. (Pubitemid 38453299)
20. high osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J. Bone Miner. Res. 19: 207-213.
21. Glantschnig, H., J. E. Fisher, G. Wesolowski, G. A. Rodan, and A. A. Reszka. 2003. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 10: 1165-1177. (Pubitemid 37258582)
22. Kudo, O., Y. Fujikawa, I. Itonaga, A. Sabokbar, T. Torisu, and N. A. Athanasou. 2002. Proinflammatory cytokine (TNFα/IL-1α) induction of human osteoclast formation. J. Pathol. 198: 220-227. (Pubitemid 35243880)
23. Weiss, R. J., H. Erlandsson Harris, M. C. Wick, P. Wretenberg, A. Stark, and K. Palmblad. 2005. Morphological characterization of receptor activator of NFκB ligand (RANKL) and IL-1β expression in rodent collagen-induced arthritis. Scand. J. Immunol. 62: 55-62.
24. Ma, T., K. Miyanishi, A. Suen, N. J. Epstein, T. Tomita, R. L. Smith, and S. B. Goodman. 2004. Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-α. Cytokine 26: 138-144. (Pubitemid 38596924)
25. Hirayama, T., A. Sabokbar, I. Itonaga, S. Watt-Smith, and N. A. Athanasou. 2001. Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease. J. Pathol. 195: 624-630. (Pubitemid 34030802)
26. Hofbauer, L. C., D. L. Lacey, C. R. Dunstan, T. C. Spelsberg, B. L. Riggs, and S. Khosla. 1999. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25: 255-259.
27. +) T cells in bone resorption lesion of periodontal disease. Clin. Exp. Immunol. 148: 271-280.
28. 2+ signaling. J. Immunol. 175: 917-925.
29. Moreno, J. L., M. Kaczmarek, A. D. Keegan, and M. Tondravi. 2003. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. Blood 102: 1078-1086.
30. Abu-Amer, Y. 2001. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB. J. Clin. Invest. 107: 1375-1385. (Pubitemid 32522031)
31. Bendixen, A. C., N. K. Shevde, K. M. Dienger, T. M. Willson, C. D. Funk, and J. W. Pike. 2001. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ1. Proc. Natl. Acad. Sci. USA 98: 2443-2448.
32. Gorny, G., A. Shaw, and M. J. Oursler. 2004. IL-6, LIF, and TNF-α regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp. Cell Res. 294: 149-158. (Pubitemid 38229789)
33. Kwan Tat, S., M. Padrines, S. Theoleyre, D. Heymann, and Y. Fortun. 2004. IL-6, RANKL, TNF-α/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 15: 49-60.
34. Kudo, O., A. Sabokbar, A. Pocock, I. Itonaga, Y. Fujikawa, and N. A. Athanasou. 2003. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 1-7. (Pubitemid 36173806)
35. Wong, P. K., J. M. Quinn, N. A. Sims, A. van Nieuwenhuijze, I. K. Campbell, and I. P. Wicks. 2006. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54: 158-168.
36. Lubberts, E., L. van den Bersselaar, B. Oppers-Walgreen, P. Schwarzenberger, C. J. Coenen-de Roo, J. K. Kolls, L. A. Joosten, and W. B. van den Berg. 2003. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J. Immunol. 170: 2655-2662. (Pubitemid 36245658)
37. Kotake, S., N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M. T. Gillespie, et al. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103: 1345-1352. (Pubitemid 29218305)
38. Lubberts, E., M. I. Koenders, and W. B. van den Berg. 2005. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 7: 29-37. (Pubitemid 40214525)
39. Josien, R., H. L. Li, E. Ingulli, S. Sarma, B. R. Wong, M. Vologodskaia, R. M. Steinman, and Y. Choi. 2000. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191: 495-502.
40. Wong, B. R., R. Josien, and Y. Choi. 1999. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukocyte Biol. 65: 715-724.
41. Bromley, M., and D. E. Woolley. 1984. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 27: 968-975. (Pubitemid 14004758)
42. Bromley, M., and D. E. Woolley. 1984. Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum. 27: 857-863. (Pubitemid 14067780)
43. Gravallese, E. M., Y. Harada, J. T. Wang, A. H. Gorn, T. S. Thornhill, and S. R. Goldring. 1998. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152: 943-951.
44. Takayanagi, H. 2005. Osteoimmunological insight into bone damage in rheumatoid arthritis. Mod. Rheumatol. 15: 225-231. (Pubitemid 41236269)
45. Josien, R., B. R. Wong, H. L. Li, R. M. Steinman, and Y. Choi. 1999. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162: 2562-2568. (Pubitemid 29309274)
46. Wong, B. R., J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F. S. Bartlett III, W. N. Frankel, et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272: 25190-25194. (Pubitemid 27415705)
47. Takayanagi, H. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7: 292-304. (Pubitemid 46480961)
48. Darveau, R. P., A. Tanner, and R. C. Page. 1997. The microbial challenge in periodontitis. Periodontology 2000 14: 12-32.
49. Gemmell, E., K. Yamazaki, and G. J. Seymour. 2007. The role of T cells in periodontal disease: homeostasis and autoimmunity. Periodontology 2000 43: 14-40.
50. Ivanyi, L., and T. Lehner. 1970. Stimulation of lymphocyte transformation by bacterial antigens in patients with periodontal disease. Arch. Oral Biol. 15: 1089-1096.
51. Baker, P. J., J. Garneau, L. Howe, and D. C. Roopenian. 2001. T-cell contributions to alveolar bone loss in response to oral infection with Porphyromonas gingivalis. Acta Odontol. Scand. 59: 222-225.
52. Taubman, M. A., and T. Kawai. 2001. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. Crit. Rev. Oral Biol. Med. 12: 125-135.
53. Teng, Y. T. 2003. The role of acquired immunity and periodontal disease progression. Crit. Rev. Oral Biol. Med. 14: 237-252. (Pubitemid 44560794)
54. Teng, Y. T., H. Nguyen, X. Gao, Y. Y. Kong, R. M. Gorczynski, B. Singh, R. P. Ellen, and J. M. Penninger. 2000. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. Invest. 106: R59-67.
55. Kiesel, J., C. Miller, Y. Abu-Amer, and R. Aurora. 2007. Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. Dev. Dyn. 236: 2181-2197. (Pubitemid 47293761)
56. Abbas, S., J. C. Clohisy, and Y. Abu-Amer. 2003. Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J. Orthop. Res. 21: 1041-1048. (Pubitemid 37322386)
57. Kim, C. H., L. M. Pelus, J. R. White, and H. E. Broxmeyer. 1998. Differential chemotactic behavior of developing T cells in response to thymic chemokines. Blood 91: 4434-4443.
58. Shen, Z., G. Reznikoff, G. Dranoff, and K. L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158: 2723-2730. (Pubitemid 127470530)
59. Lacey, D. L., E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
60. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602. (Pubitemid 28173173)
61. Clohisy, J. C., E. Frazier, T. Hirayama, and Y. Abu-Amer. 2003. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. J. Orthop. Res. 21: 202-212.
62. Takayanagi, H., H. Iizuka, T. Juji, T. Nakagawa, A. Yamamoto, T. Miyazaki, Y. Koshihara, H. Oda, K. Nakamura, and S. Tanaka. 2000. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43: 259-269. (Pubitemid 30395733)
63. Zhang, Z., E. Jimi, and A. L. Bothwell. 2003. Receptor activator of NF-κB ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. J. Immunol. 171: 3620-3626. (Pubitemid 37254565)
64. Viola, A., R. L. Contento, and B. Molon. 2006. T cells and their partners: the chemokine dating agency. Trends Immunol. 27: 421-427. (Pubitemid 44216192)
65. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27. (Pubitemid 24035278)
66. Roitt, I. M., J. Brostoff, and D. K. Male. 2001. Immunology. Mosby, New York.
67. Robertson, J. M., P. E. Jensen, and B. D. Evavold. 2000. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol. 164: 4706-4712.
68. Schwarz, K., R. de Giuli, G. Schmidtke, S. Kostka, M. van den Broek, K. B. Kim, C. M. Crews, R. Kraft, and M. Groettrup. 2000. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J. Immunol. 164: 6147-6157. (Pubitemid 30408791)
69. Lee, K. H., A. R. Dinner, C. Tu, G. Campi, S. Raychaudhuri, R. Varma, T. N. Sims, W. R. Burack, H. Wu, J. Wang, et al. 2003. The immunological synapse balances T cell receptor signaling and degradation. Science 302: 1218-1222.
70. Prlic, M., M. A. Williams, and M. J. Bevan. 2007. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr. Opin. Immunol. 19: 315-319. (Pubitemid 46687015)
71. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
72. Gao, Y., F. Grassi, M. R. Ryan, M. Terauchi, K. Page, X. Yang, M. N. Weitzmann, and R. Pacifici. 2007. IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest. 117: 122-132. (Pubitemid 46048459)
73. Takaoka, A., and T. Taniguchi. 2003. New aspects of IFN-α/β signalling in immunity, oncogenesis and bone metabolism. Cancer Sci. 94: 405-411. (Pubitemid 36790470)
74. Kamolmatyakul, S., W. Chen, and Y. P. Li. 2001. Interferon-γ down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J. Dent. Res. 80: 351-355.
75. Rodriguiz, R. M., L. L. Key, Jr., and W. L. Ries. 1993. Combination macrophage-colony stimulating factor and interferon-γ administration ameliorates the osteopetrotic condition in microphthalmic (mi/mi) mice. Pediatr. Res. 33: 384-389.
76. Key, L. L. Jr., R. M. Rodriguiz, S. M. Willi, N. M. Wright, H. C. Hatcher, D. R. Eyre, J. K. Cure, P. P. Griffin, and W. L. Ries. 1995. Long-term treatment of osteopetrosis with recombinant human interferon γ. N. Engl. J. Med. 332: 1594-1599
77. Vermeire, K., H. Heremans, M. Vandeputte, S. Huang, A. Billiau, and P. Matthys. 1997. Accelerated collagen-induced arthritis in IFN-γ receptor-deficient mice. J. Immunol. 158: 5507-5513. (Pubitemid 127681260)
78. Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
79. Kuivaniemi, H., G. Tromp, and D. J. Prockop. 1997. Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. Hum. Mutat. 9: 300-315. (Pubitemid 27157648)
80. Xu, L., A. L. Anderson, Q. Lu, and J. Wang. 2007. Role of fibrillar structure of collagenous carrier in bone sialoprotein-mediated matrix mineralization and osteoblast differentiation. Biomaterials 28: 750-761. (Pubitemid 44647453)
81. Williams, R. O. 2004. Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol. Med. 98: 207-216.
82. Brand, D. D., A. H. Kang, and E. F. Rosloniec. 2003. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. 25: 3-18.
83. Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. Yasayko, J. E. Wilkinson, D. Galas, S. F. Ziegler, and F. Ramsdell. 2001. Disruption of a new forkhead/winged-helix protein, Scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat, Genet. 27: 68-73.
84. Ochs, H. D., E. Gambineri, and T. R. Torgerson. 2007. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 38: 112-121.
85. + regulatory T cells. Nat. Immunol. 4: 330-336.
86. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061. (Pubitemid 36222930)
87. + T regulatory cells. Nat. Immunol. 4: 337-342.
88. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775-787.
89. Elias, K. M., A. Laurence, T. S. Davidson, G. Stephens, Y. Kanno, E. M. Shevach, and J. J. O'Shea. 2008. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111: 1013-1020.
90. + regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J. Immunol. 179: 4685-4693.
91. + T regulatory cells. J. Immunol. 178: 4022-4026.
92. + single positive T cells. Transplantation 82: 953-964.
93. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
94. Selvaraj, R. K., and T. L. Geiger. 2007. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-β. J. Immunol. 178: 7667-7677.
95. Gershon, R. K., and K. Kondo. 1970. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18: 723-737.
96. + immunoregulatory cells. J. Immunol. 167: 1137-1140.
97. Shevach, E. M. 2006. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25: 195-201. (Pubitemid 44224153)
98. + Treg-mediated suppression. Trends Immunol. 29: 337-342.
99. + T regulatory cells. Curr. Opin. Immunol. 20: 327-331.
100. + T suppressor cells are back to the game: are they players in autoimmunity? Autoimmun. Rev. 1: 279-283.
101. + regulatory T cells in human ovarian carcinoma. Cancer Res. 65: 5020-5026.
102. Gilliet, M., and Y. J. Liu. 2002. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195: 695-704. (Pubitemid 34259715)
103. + T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J. Immunol. 179: 4323-4334.
104. + T cells. J. Immunol. 175: 7093-7097.
105. + T suppressor cell function in patients with active systemic lupus erythematosus. J. Immunol. 166: 6452-6457.
106. + T cells fine-tune the myelin basic protein-reactive T cell receptor Vβ repertoire during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 100: 8378-8383.
107. + T cells in EAE mice. Proc. Natl. Acad. Sci. USA 98: 6301-6306.
108. + T cell mediated regulatory pathway. Cell. Mol. Immunol. 2: 161-167.
109. + regulatory T cells recognize activated T cells via conventional MHC class I-αβTCR interaction and become IL-10-producing active regulatory cells. Int. Immunol. 20: 937-947.
110. + regulatory T cells in the maintenance of T cell homeostasis. J. Exp. Med. 200: 1123-1134.
111. + regulatory T cells. Mol. Immunol. 45: 2937-2950